Journal article
Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial
ML Schilsky, A Czlonkowska, M Zuin, D Cassiman, C Twardowschy, A Poujois, FDAA Gondim, G Denk, RG Cury, P Ott, J Moore, A Ala, R D'Inca, E Couchonnal-Bedoya, K D'Hollander, N Dubois, COF Kamlin, KH Weiss, U To, A Patel Show all
Lancet Gastroenterology and Hepatology | Published : 2022
Abstract
Background: Wilson disease is an inherited disorder of copper transport. Whereas penicillamine is used therapeutically to re-establish copper balance, trientine is indicated for patients with penicillamine intolerance. We aimed to compare penicillamine with trientine tetrahydrochloride (TETA4) for maintenance therapy in patients with Wilson disease. Methods: We conducted a randomised, open-label, non-inferiority, phase 3 trial at 15 health-care centres across nine countries (patients were recruited from 13 of these health-care centres across Brazil, Europe, and the USA). We enrolled patients aged 18–75 years with stable Wilson disease who were treated for at least 1 year with penicillamine. ..
View full abstract